Skip to main content

Table 3 History of IgRT

From: Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort “Visages”

  N = 116   
Age at start of IgRT (years) 115a 33.34 ± 20.17 [0–79.7; 33.6]
Duration of IgRT (years) 115a 8.5 ± 8.4 [0.2–38.5; 5.6]
History of at least one switch from IVIg to SCIg 49 42.2 %  
History of at least one switch from SCIg to IVIg 14 12.1 %  
Route of IgRT at enrollment    
• IVIg at hospital 46 39.7 %  
• IVIg at home 13 11.2 %  
• SCIg at home 57 49.1 %)  
Switch from IVIg to SCIg after enrollment 11 9.5 %  
Switch from SCIg to IVIg after enrollment 2 1.7 %  
Switch from hospital-based to home-based IgRT 12 10.3 %  
Switch from home-based to hospital-based IgRT 2 1.7 %  
  1. amissing data for one patient